VXRT
Vaxart, Inc.
OTC Markets OTCQXUSDEQUITY
Healthcare
DELAYED
Sell
-53/100
Last price
0.43
▲ 0.01 (2.52%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.42
Prev close
0.42
Day high
0.45
Day low
0.42
Volume
27.52K
Market cap
$107.23M
P/E (TTM)
2.59
52W range
0.31 – 0.84
Day trading desk
Gap from prior close
0.00%
Prior close 0.42
VWAP
0.44
-2.01% from price
Relative volume
0.10×
Quiet session
Session range
7.14%
0.42 – 0.45
Position in range
35%
Mid range
ATR (14D)
0.03
7.46% of price
Prior day high
0.45
PDH
Prior day low
0.40
PDL
Bid / ask spread
—
Quote not published
Session volume
27.52K
Avg 286.46K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.22%
-4.2%
1M
-12.00%
-13.2%
3M
-20.00%
-24.5%
6M
-29.03%
-47.2%
YTD
+25.71%
+11.5%
1Y
+22.22%
+5.8%
3Y
-41.33%
-123.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on VXRT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.46M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 16, 26 | HERON ELAINE J Director |
— | 39.40K | — | Direct |
| Jul 16, 26 | FINNEY KEVIN Director |
— | 39.40K | — | Direct |
| Jul 16, 26 | BREITMEYER JAMES B Director |
— | 8.31K | — | Direct |
| Jul 16, 26 | WATSON WILLIAM MARK Director |
— | 39.40K | — | Direct |
| Jul 16, 26 | WHEADON DAVID E. Director |
— | 39.40K | — | Direct |
| May 22, 26 | WATSON WILLIAM MARK Director |
BUY | 10.00K | $6.53K | Direct |
| Apr 23, 26 | BREITMEYER JAMES B Director |
— | 78.80K | — | Direct |
| Mar 16, 26 | GRASMAN JEROEN NICOLAAS Chief Financial Officer |
— | 227.00K | — | Direct |
| Mar 16, 26 | LO STEVEN Chief Executive Officer |
— | 846.50K | — | Direct |
| Mar 16, 26 | TUCKER SEAN N. Officer |
— | 200.00K | — | Direct |
| Mar 16, 26 | CUMMINGS JAMES F. Officer |
— | 227.00K | — | Direct |
| Mar 16, 26 | BERG EDWARD B General Counsel |
— | 115.00K | — | Direct |
| Dec 4, 25 | LO STEVEN Chief Executive Officer |
— | 151.35K | — | Direct |
| Nov 17, 25 | HERON ELAINE J Director |
BUY | 40.00K | $15.92K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BERG EDWARD B |
General Counsel | 799.86K | Stock Award(Grant) |
CUMMINGS JAMES F. |
Officer | 964.79K | Stock Award(Grant) |
FINNEY KEVIN |
Director | 244.17K | Stock Award(Grant) |
FINNEY MICHAEL JOSEPH |
Director | 702.84K | Stock Award(Grant) |
GRASMAN JEROEN NICOLAAS |
Chief Financial Officer | 577.00K | Stock Award(Grant) |
HERON ELAINE J |
Director | 135.97K | Stock Award(Grant) |
LEE PHILLIP E. |
Chief Financial Officer | 631.62K | Stock Award(Grant) |
LO STEVEN |
Chief Executive Officer | 2.73M | Stock Award(Grant) |
TUCKER SEAN N. |
Officer | 991.75K | Stock Award(Grant) |
WATSON WILLIAM MARK |
Director | 173.53K | Stock Award(Grant) |
Fundamentals
Market cap$107.23M
Enterprise value$54.50M
Revenue (TTM)$243.06M
Gross profit$58.80M
EBITDA$45.62M
Net income$38.59M
EPS (TTM)$0.17
Free cash flow$-17.15M
Total cash$63.98M
Total debt$12.54M
Book value / share$0.39
Shares outstanding243.70M
Float239.25M
Short % of float7.51%
Dividend yield0.00%
Beta (5Y)1.06
Valuation & profitability ratios
Trailing P/E2.59
Forward P/E-0.43
PEG ratio—
Price / sales—
Price / book1.13
EV / revenue0.22
EV / EBITDA1.20
Gross margin24.19%
Operating margin-48.45%
Profit margin15.88%
Return on equity66.97%
Return on assets15.04%
Debt / equity15.22
Current ratio1.60
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $237.26M | $28.70M | $7.38M | $107.00K | +726.7% |
| Operating revenue | $237.26M | $28.70M | $7.38M | $107.00K | +726.7% |
| Research & development | $201.58M | $74.21M | $68.14M | $81.05M | +171.6% |
| Selling, general & admin | $17.61M | $20.78M | $22.58M | $29.39M | -15.3% |
| Total operating expense | $219.18M | $94.99M | $90.73M | $110.44M | +130.7% |
| Operating income | $18.07M | -$66.29M | -$83.35M | -$110.33M | +127.3% |
| Net interest income | -$1.23M | -$426.00K | $1.21M | -$58.00K | -188.0% |
| Pre-tax income | $16.80M | -$66.69M | -$82.20M | -$107.69M | +125.2% |
| Tax provision | $476.00K | $260.00K | $261.00K | $67.00K | +83.1% |
| Net income | $16.33M | -$66.95M | -$82.47M | -$107.76M | +124.4% |
| Net income to common | $16.33M | -$66.95M | -$82.47M | -$107.76M | +124.4% |
| Basic EPS | 0.07 | -0.33 | -0.57 | -0.84 | +121.2% |
| Diluted EPS | 0.07 | -0.33 | -0.57 | -0.84 | +121.2% |
| EBIT | $19.63M | -$63.72M | -$80.76M | -$106.39M | +130.8% |
| EBITDA | $28.20M | -$54.87M | -$72.13M | -$100.58M | +151.4% |
| Basic shares | 230.27M | 202.14M | 144.82M | 127.68M | +13.9% |
| Diluted shares | 230.35M | 202.14M | 144.82M | 127.68M | +14.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $53.81M | $25.23M | $34.76M | $46.01M | +113.3% |
| Cash & short-term investments | $63.81M | $51.72M | $39.71M | $95.72M | +23.4% |
| Accounts receivable | $14.56M | $5.76M | $3.01M | $20.00K | +152.8% |
| Total current assets | $136.12M | $68.26M | $45.54M | $99.45M | +99.4% |
| Property, plant & equipment | $16.83M | $29.11M | $36.57M | $41.30M | -42.2% |
| Goodwill & intangibles | $7.33M | $8.06M | $8.80M | $9.53M | -9.1% |
| Total assets | $186.08M | $166.39M | $91.83M | $153.85M | +11.8% |
| Total current liabilities | $86.75M | $90.88M | $13.72M | $17.92M | -4.5% |
| Total debt | $8.98M | $17.53M | $20.09M | $21.70M | -48.7% |
| Total liabilities | $98.28M | $107.46M | $34.02M | $43.25M | -8.5% |
| Retained earnings | -$460.19M | -$476.52M | -$409.57M | -$327.11M | +3.4% |
| Shareholder equity | $87.80M | $58.92M | $57.80M | $110.60M | +49.0% |
| Working capital | $49.37M | -$22.62M | $31.81M | $81.53M | +318.3% |
| Net tangible assets | $80.46M | $50.86M | $49.01M | $101.07M | +58.2% |
| Shares issued | 240.74M | 228.20M | 153.96M | 134.20M | +5.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $16.33M | -$66.95M | -$82.47M | -$107.76M | +124.4% |
| Depreciation & amortisation | $8.58M | $8.85M | $8.62M | $5.80M | -3.1% |
| Stock-based compensation | $8.31M | $11.50M | $14.13M | $13.59M | -27.7% |
| Change in working capital | -$22.56M | $3.26M | -$10.85M | -$4.70M | -791.7% |
| Operating cash flow | $7.71M | -$44.76M | -$70.45M | -$94.78M | +117.2% |
| Capital expenditure | -$145.00K | -$554.00K | -$1.87M | -$9.60M | +73.8% |
| Investing cash flow | $16.63M | -$21.32M | $43.95M | -$20.41M | +178.0% |
| Financing cash flow | $4.24M | $56.56M | $15.24M | $17.46M | -92.5% |
| Free cash flow | $7.57M | -$45.32M | -$72.32M | -$104.38M | +116.7% |
| End cash position | $53.81M | $25.23M | $34.76M | $46.01M | +113.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $27.18M | $39.23M | $104.24M | $72.41M | $39.73M | — | -30.7% |
| Operating revenue | $27.18M | $39.23M | $104.24M | $72.41M | $39.73M | — | -30.7% |
| Research & development | $33.75M | $29.41M | $45.15M | $75.95M | $49.73M | — | +14.8% |
| Selling, general & admin | $6.60M | $4.64M | $3.67M | $4.28M | $4.60M | — | +42.3% |
| Total operating expense | $40.36M | $34.05M | $48.82M | $80.22M | $54.33M | — | +18.5% |
| Operating income | -$13.17M | $5.17M | $55.42M | -$7.81M | -$14.60M | — | -354.6% |
| Net interest income | $40.00K | $46.00K | $1.00K | -$306.00K | -$362.00K | — | -13.0% |
| Pre-tax income | -$13.46M | $5.21M | $55.39M | -$8.12M | -$14.97M | — | -358.5% |
| Tax provision | $29.00K | $29.00K | $344.00K | $17.00K | $20.00K | — | 0.0% |
| Net income | -$13.49M | $5.18M | $55.05M | -$8.14M | -$14.99M | — | -360.6% |
| Net income to common | -$13.49M | $5.18M | $55.05M | -$8.14M | -$14.99M | — | -360.6% |
| Basic EPS | -0.06 | 0.02 | — | -0.04 | -0.07 | -0.07 | -400.0% |
| Diluted EPS | -0.06 | 0.02 | — | -0.04 | -0.07 | -0.07 | -400.0% |
| EBIT | -$12.93M | $5.71M | $55.94M | -$7.52M | -$14.29M | — | -326.3% |
| EBITDA | -$12.19M | $6.84M | $57.99M | -$5.44M | -$12.10M | — | -278.2% |
| Basic shares | 242.17M | 240.65M | — | 228.93M | 228.37M | 227.92M | +0.6% |
| Diluted shares | 242.17M | 242.18M | — | 228.93M | 228.37M | 227.92M | -0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $50.93M | $50.75M | $53.81M | $16.88M | $20.11M | +0.4% |
| Cash & short-term investments | $63.98M | $61.02M | $63.81M | $28.79M | $26.27M | +4.8% |
| Accounts receivable | $11.00K | $7.14M | $14.56M | $42.72M | $4.28M | -99.8% |
| Total current assets | $116.69M | $131.70M | $136.12M | $117.37M | $70.38M | -11.4% |
| Property, plant & equipment | $15.71M | $15.47M | $16.83M | $23.16M | $25.06M | +1.5% |
| Goodwill & intangibles | $6.97M | $7.15M | $7.33M | $7.52M | $7.70M | -2.5% |
| Total assets | $165.19M | $180.06M | $186.08M | $208.99M | $164.09M | -8.3% |
| Total current liabilities | $73.11M | $76.84M | $86.75M | $169.30M | $117.88M | -4.9% |
| Total debt | $7.81M | $7.97M | $8.98M | $15.44M | $16.11M | -2.0% |
| Total liabilities | $82.81M | $85.94M | $98.28M | $182.23M | $131.21M | -3.6% |
| Retained earnings | -$468.51M | -$455.02M | -$460.19M | -$515.24M | -$507.10M | -3.0% |
| Shareholder equity | $82.37M | $94.12M | $87.80M | $26.76M | $32.88M | -12.5% |
| Working capital | $43.58M | $54.86M | $49.37M | -$51.93M | -$47.50M | -20.6% |
| Net tangible assets | $75.40M | $86.97M | $80.46M | $19.24M | $25.18M | -13.3% |
| Shares issued | 242.84M | 242.17M | 240.74M | 229.47M | 229.42M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$13.49M | $5.18M | $55.05M | -$8.14M | -$14.99M | — | -360.6% |
| Depreciation & amortisation | $741.00K | $1.13M | $2.06M | $2.08M | $2.20M | — | -34.2% |
| Stock-based compensation | $1.29M | $1.48M | $1.72M | $2.02M | $2.12M | — | -13.0% |
| Change in working capital | $13.49M | -$9.97M | -$27.66M | $6.07M | -$4.40M | — | +235.4% |
| Operating cash flow | $2.78M | -$2.05M | $30.66M | $2.60M | -$15.95M | — | +235.2% |
| Capital expenditure | -$35.00K | -$448.00K | -$1.00K | -$117.00K | — | -$130.00K | +92.2% |
| Investing cash flow | -$2.72M | -$676.00K | $1.99M | -$5.82M | $7.23M | — | -301.8% |
| Financing cash flow | $121.00K | -$338.00K | $4.28M | -$4.00K | $125.00K | — | +135.8% |
| Free cash flow | $2.74M | -$2.50M | $30.66M | $2.48M | -$15.84M | — | +209.6% |
| End cash position | $50.93M | $50.75M | $53.81M | $16.88M | $20.11M | — | +0.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.21 | -0.06 | +71.4% |
| Mar 2026 | 0.02 | 0.02 | 0.0% |
| Dec 2025 | -0.08 | 0.24 | +400.0% |
| Sep 2025 | -0.07 | -0.04 | +38.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.31 | 1 | $27.20M | -62.4% |
| Next quarter | -0.19 | 1 | $25.00M | -76.0% |
| Current year | -0.68 | 1 | $118.60M | -50.0% |
| Next year | -1.03 | 1 | $2.35M | -98.0% |
Analyst targets & ownership
Mean target$3.33
High target$4.00
Low target$2.00
Implied upside674.11%
Analyst count3
ConsensusNONE
Strong buy / Buy0 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders1.42%
Held by institutions0.05%
Institutions holding7
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.45
-3.88% from price
SMA 20
0.47
-5.88% from price
SMA 50
0.50
-12.32% from price
SMA 100
0.54
-20.08% from price
SMA 200
0.59
-25.05% from price
EMA 12
0.45
-4.64% from price
EMA 26
0.47
-8.47% from price
EMA 50
0.49
-12.93% from price
RSI (14)
37.8
Neutral
MACD (12,26,9)
-0.02
Hist -0.00
ATR (14)
0.03
7.31% of price
Realised vol 30D
38.6%
Annualised
Bollinger upper
0.51
20, 2σ
Bollinger lower
0.42
20, 2σ
50 / 200 cross
Death
0.50 vs 0.59
Trend bias
Below 200
-25.05%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.84
Less volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
38.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-47.5%
Peak to trough
Max drawdown 5Y
-96.2%
Peak to trough
ATR 14
0.03
7.31% of price
Beta (reported)
1.06
5Y monthly, from filing
Short interest
Shares short
16.96M
Prior 14.68M
Change vs prior
+15.6%
Shorts adding
% of float
7.51%
Normal
% of shares out
7.41%
Against total outstanding
Days to cover
1.9
Liquid
Float
239.25M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 27, 25 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Aug 15, 24 | Oppenheimer | INITIATED | — | Outperform |
| Jan 31, 24 | B. Riley Securities | UPGRADE | Neutral | Buy |
| Sep 7, 23 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Aug 7, 23 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Dec 19, 22 | B. Riley Securities | MAINTAINED | — | Neutral |
| Sep 2, 22 | Cantor Fitzgerald | MAINTAINED | — | Overweight |
| May 19, 22 | B. Riley Securities | MAINTAINED | — | Neutral |
| Nov 2, 21 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Jun 30, 21 | B. Riley Securities | DOWNGRADE | Buy | Neutral |
| Jun 24, 21 | Jefferies | INITIATED | — | Buy |
| Jun 11, 21 | Piper Sandler | INITIATED | — | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend dateNov 9, 2012
Next pay dateFeb 14, 2018
Last split1:11
Split dateFeb 14, 2018
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-14
Corporate Changes & Voting Matters
8-K · 2026-08-25
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-28
Corporate Changes & Voting Matters
8-K · 2026-07-17
Corporate Changes & Voting Matters
8-K · 2026-07-07
Proxy Statements
DEFA14A · 2026-07-06
Proxy Statements
DEFA14A · 2026-07-02
Headlines
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference
MarketBeat · 22d ago
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 29d ago
Vaxart Secures New European Patent Covering Oral Norovirus Vaccine Technology
MT Newswires · 41d ago
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
GlobeNewswire · 41d ago
Vaxart Inc (VXRT) (Q2 2026) Earnings Call Highlights: Oral COVID Vaccine Shows Promise, Cash ...
GuruFocus.com · 57d ago
Vaxart Q2 Earnings Call Highlights
MarketBeat · 58d ago
Vaxart, Inc. Q2 2026 Earnings Call Summary
Moby · 61d ago
Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results
GlobeNewswire · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.